FeesSafety
Pluang+

Savers Value Village remains a Buy despite 14.7% share drop and lowered 2026 outlook.

Analyst Insights
18 Nov 2026, 17:41 WIB
Seeking Alpha
View Source
Bullish
Savers Value Village remains a Buy despite 14.7% share drop and lowered 2026 outlook.

Savers Value Village (SVV) maintains a Buy rating despite a 14.7% decline in its share price and a lowered guidance for 2026. The company shows strong fundamentals with Q3 revenue up 8.5%, net profit turning positive at $23.4 million from a previous loss, and EBITDA increasing to $75.9 million. SVV is expanding with 20 new stores year-over-year and innovating with tools like ThriftIQ and Autotagger to boost efficiency and long-term value. Shares are attractively priced based on cash flow and EBITDA, with management focused on growth, innovation, and improving margins.

Savers Value Village is the subject, with this market snapshot from Pluang as of Nov 18, 2026 22:12 WIB: Among 134 Consumer Cyclical-sector US stocks priced on Pluang, 92 rose and 40 fell today. Notable movers include GLBE at USD 36.47 with a 1-day change of -8.39% and a typical hold time of 21 days, NEGG at USD 8.34 up 7.20% but with 100% sell order activity, and VIK at USD 99.47 up 5.50% with 100% buy order activity. The most notable figure is NEGG's full sell order activity despite its price rise.

More News

Global pharmaceutical market to hit $3.2T by 2035, led by obesity and cancer drug growth amid US tariff shifts

Global pharmaceutical market to hit $3.2T by 2035, led by obesity and cancer drug growth amid US tariff shifts

The global pharmaceutical market is projected to grow from $1.88 trillion in 2026 to $3.20 trillion by 2035, driven mainly by obesity and oncology drugs. The U.S. market, holding 42% of the global share, faces new tariffs linked to pricing deals and ...

Bullish
53 minutes ago
LEQEMBI slows Alzheimer's progression by 76% over 3 years in real-world study of 560 patients.

LEQEMBI slows Alzheimer's progression by 76% over 3 years in real-world study of 560 patients.

A new three-year real-world study of 560 early Alzheimer's patients treated with LEQEMBI showed a 76% reduction in progression to moderate or severe dementia compared to a matched control group. Over 81% of patients remained stable or improved after ...

Market News
Bullish
53 minutes ago
Fox Factory wins seventh straight Baja 1000 and sweeps 2026 SCORE off-road championships

Fox Factory wins seventh straight Baja 1000 and sweeps 2026 SCORE off-road championships

Fox Factory Holding Corp. celebrated its seventh consecutive overall victory at the 2026 SCORE Baja 1000, with FOX Shocks and Method Race Wheels powering the winning team. The company’s equipment helped athletes sweep all four 2026 SCORE Internationa...

Market News
Bullish
53 minutes ago
Global automotive actuators market to grow to $40.3B by 2033 driven by electrification and automation

Global automotive actuators market to grow to $40.3B by 2033 driven by electrification and automation

The global automotive actuators market, valued at $29.3 billion in 2025, is projected to grow to $40.3 billion by 2033 at a CAGR of 4.4%. Growth is fueled by rising electric vehicle production, advanced safety systems, and automation technologies. As...

Market News
Bullish
53 minutes ago
TJX Companies beats Q3 sales estimates; shares jump 10% on strong international growth and holiday optimism.

TJX Companies beats Q3 sales estimates; shares jump 10% on strong international growth and holiday optimism.

The TJX Companies reported Q3 FY2027 revenue of $16 billion, beating estimates with a 5.5-6% year-over-year increase. Comparable store sales grew 4%, led by strong international segment performance, while the domestic Marmaxx group showed slower grow...

Company Fundamentals
Bullish
56 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App